This diagnostic screen identified 28.8% of patients across disease subtypes and led to the identification of 11 tumor-associated antigens (CTAG2, MAGEB4, SHARPIN, MAGEA12, MAGEA4, MRFAP1L1, PNMA2, AURKA, SERPINB1, XAGE3 and BAGE4) with detectable antibodies exclusive to cancer patients, including several cancer-testis antigens. This evidence concerns the gene MAGEA4 and neoplasm.